Thursday, 7 November 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 November 2024
News

Kidney drug hits another hurdle

Posted 5 November 2024 AM

Despite winning a surprisingly broad indication for Idefirix in Australia, Hansa Biopharma has hit yet another hurdle in gaining public funding for the kidney desensitisation treatment.

An application requesting funding for Idefirix under the National Health Reform Agreement was knocked back by the Medical Services Advisory Committee (MSAC) in October 2023 after being considered at the July 2023 meeting. Idefirix is intended as a desensitisation treatment of highly sensitised (HS) adult kidney transplant patients with a positive crossmatch against an available deceased or living donor who are unlikely to be transplanted under current kidney allocation systems.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (15)

Access & Reimbursement (1)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (3)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.